


## WuXi Biology

# In Silico Drug Discovery Platform

### In Silico Tools for Drug Discovery




#### In Silico Services for Hit Finding

	Structure Based	Ligand Based					
VS	Co-crystal or AF2 Predicted Structure	3D shape based	Pharmacophore VS	based 2D Fingerprint based			
Diversity	5 Million	20 Million	5 Million	1 Billion			
Libraries Source for VS		WuXi AppTec GalaXi (20 Million) Commercial Vendors (10 Billion)					
Service Model	FFS/Customization Services tailored to specific needs						
Timeline	4 to 5 weeks		3 to 4 weeks				
Note	Co-crystal / predicted structure needed	Query molecule needed					
	DEL / ASMS Enhanced VS						
			•	DEL + ASMS			
Experimental + VS Combo	DEL	A	SMS	DEL			
•	DEL + ML		SMS IS + ML	DEL + ASMS DEL + ASMS + ML			
•	DEL + ML 10 Billion			DEL + ASMS + ML			
+ VS Combo			IS + ML	DEL + ASMS + ML			
+ VS Combo Diversity Libraries	10 Billion GalaXi, Enamine, Mcule	•< ASM	IS + ML 270	DEL + ASMS + ML			




# WuXi Biology

#### **Representative Workflow & Case Studies for Hit Finding**




## Hit to Lead & Lead Optimization

#### **Molecular Dynamics Platform**



Proteins



RNA in Aqueous Solution

#### **ADMET Prediction Model**

Category	Prediction Metrics	Model	Category	Prediction Metrics	Model
Absorption	Caco-2 cell permeability     MDCK cell permeability     PAMPA permeability     Kinetic solubility     Thermodynamic solubility	<ul> <li>XGBoost</li> <li>Random Forest</li> </ul>	Metabolism	• CYP450	<ul> <li>Deep Learning</li> </ul>
			Excretion	Clearance_Hepatocyte     Clearance_Microsome     T1/2	Deep Learning
Distribution	BBB Score	<ul> <li>Polynomial Regression</li> </ul>	Toxicity	<ul><li>hERG Blocker</li><li>Tox21 (ER, AR pathway)</li></ul>	Deep     Learning



#### **Contact Us**

BD USA: mahnaz\_arjomand@wuxiapptec.com BD EU/UK/Israel: dave\_madge@wuxiapptec.com BD China: xu\_longji@wuxiapptec.com BD Japan: fumio\_itoh@wuxiapptec.com BD Korea: sycho@wuxiapptec.com